Ocuphire Pharma

Ocuphire Pharma

Ocuphire Pharma is a clinical-stage ophthalmic biopharmaceutical company developing therapies for inherited retinal diseases (IRDs) and other retinal and refractive disorders. The firm's approach centers on gene therapy to address mutations causing vision loss, with a stated focus on bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa (RP). Its website describes a drug development engine designed to solve for multiple inherited blinding conditions. The company's pipeline is built around preserving vision through genetic intervention, though specific asset names, trial phases, and dosing details are not detailed on the current website. No deployment figures, partnership announcements, or co-development deals were found in the available source material. The firm has not publicly disclosed any institutional funding rounds, grant backing, or strategic collaborations. The team features Dr. Jean Bennett, a prominent figure in gene therapy research, as Scientific Advisor. No executive leadership roster, total employee count, or additional offices beyond the Farmington Hills headquarters are publicly listed. In May 2024: No recent operational events, financings, or regulatory milestones could be verified from the provided sources. Ocuphire Pharma's structural differentiator lies in its identity as a patient-centric, science-driven engine built specifically for rare IRDs, with Dr. Bennett's involvement providing a direct link to foundational gene therapy research. However, the lack of disclosed operational detail—no team size, no funding history, no named CEO—creates an unusually opaque profile for a clinical-stage biopharmaceutical company.